Overview

A First-in-Human Study of EOS301984 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

Summary

APT-008 is an open-label, Phase I/Ib, dose escalation and expansion cohort study to evaluate the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), and preliminary efficacy of EOS301984 as monotherapy and in combination with other anticancer therapies in participants with advanced solid tumors.

Phase:

PHASE1

Details

Lead Sponsor:

iTeos Therapeutics

Treatments:

spartalizumab